Zhaoke Ophthalmology Procures Distributor for Presbyopia Drug in Australia, New Zealand

Like
Comment
Favorite

Zhaoke Ophthalmology Procures Distributor for Presbyopia Drug in Australia, New Zealand

MT Newswires Live01-13

Zhaoke Ophthalmology (HKG:6622) entered into an agreement under which it is entitled to grant AFT Pharmaceuticals the exclusive rights to distribute BRIMOCHOLTM PF in Australia and New Zealand, a Monday bourse filing said.

AFT Pharmaceuticals, a manufacturer and distributor of healthcare products based in New Zealand, will obtain the relevant local drug registrations on behalf of the company to import, distribute, promote, market, and sell the drug in the region.

The ophthalmic pharmaceutical company will receive an upfront payment, as well as additional milestone payments under the contract.

BRIMOCHOLTM PF is being developed by Zhaoke Ophthalmology's in partnership with Tenpoint Therapeutics as a potential treatment for the correction of the loss of near vision associated with presbyopia.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

22:28
Trump Signs Order Imposing Sanctions on Countries Importing Venezuelan Oil -White House
22:25
Mastermyne Group - Contract Encompasses Approximately 200 Roles at Appin Mine, Others
22:25
Mastermyne Group - Executed Contract for Contract Mining Services With Gear M Illawarra Met Coal
22:20
Fortis Inc - Net Proceeds to Reduce Borrowings and for General Corporate Purposes
22:20
Fortis Inc - Prices $600 Million Offering of 4.090% Senior Unsecured Notes Due 2032

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2503104303?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-01-13 20:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503104303","market":"nz","top_or_hot":-1,"title":"Zhaoke Ophthalmology Procures Distributor for Presbyopia Drug in Australia, New Zealand","media":"MT Newswires Live","content":"<html><body><p> Zhaoke Ophthalmology (HKG:6622) entered into an agreement under which it is entitled to grant AFT Pharmaceuticals the exclusive rights to distribute BRIMOCHOLTM PF in Australia and New Zealand, a Monday bourse filing said.</p><p>AFT Pharmaceuticals, a manufacturer and distributor of healthcare products based in New Zealand, will obtain the relevant local drug registrations on behalf of the company to import, distribute, promote, market, and sell the drug in the region.</p><p>The ophthalmic pharmaceutical company will receive an upfront payment, as well as additional milestone payments under the contract.</p><p>BRIMOCHOLTM PF is being developed by Zhaoke Ophthalmology's in partnership with Tenpoint <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> as a potential treatment for the correction of the loss of near vision associated with presbyopia.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhaoke Ophthalmology Procures Distributor for Presbyopia Drug in Australia, New Zealand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhaoke Ophthalmology Procures Distributor for Presbyopia Drug in Australia, New Zealand\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-13 20:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Zhaoke Ophthalmology (HKG:6622) entered into an agreement under which it is entitled to grant AFT Pharmaceuticals the exclusive rights to distribute BRIMOCHOLTM PF in Australia and New Zealand, a Monday bourse filing said.</p><p>AFT Pharmaceuticals, a manufacturer and distributor of healthcare products based in New Zealand, will obtain the relevant local drug registrations on behalf of the company to import, distribute, promote, market, and sell the drug in the region.</p><p>The ophthalmic pharmaceutical company will receive an upfront payment, as well as additional milestone payments under the contract.</p><p>BRIMOCHOLTM PF is being developed by Zhaoke Ophthalmology's in partnership with Tenpoint <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> as a potential treatment for the correction of the loss of near vision associated with presbyopia.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2503104303","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503104303","pubTimestamp":1736770586,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Zhaoke Ophthalmology (HKG:6622) entered into an agreement under which it is entitled to grant AFT Pharmaceuticals the exclusive rights to distribute BRIMOCHOLTM PF in Australia and New Zealand, a Mond","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","XAO.AU":"标普/澳交所 普通股指数","BK1587":"次新股","NZ50G.NZ":"S&P/NZX 50","BK1574":"生物医药B类股","XJO.AU":"标普/澳交所 200指数","T10G.NZ":"S&P/NZX 10","XKO.AU":"标普/澳交所 300指数","06622":"兆科眼科-B","BK1191":"制药","NZ20C.NZ":"S&P/NZX 20"},"translate_title":"兆科眼科在澳大利亚、新西兰采购老花眼药物经销商","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06622":0.9,"NZ20C.NZ":1,"NZ50G.NZ":1,"T10G.NZ":1,"XAO.AU":1,"XJO.AU":1,"XKO.AU":1},"content_text":"Zhaoke Ophthalmology (HKG:6622) entered into an agreement under which it is entitled to grant AFT Pharmaceuticals the exclusive rights to distribute BRIMOCHOLTM PF in Australia and New Zealand, a Monday bourse filing said.AFT Pharmaceuticals, a manufacturer and distributor of healthcare products based in New Zealand, will obtain the relevant local drug registrations on behalf of the company to import, distribute, promote, market, and sell the drug in the region.The ophthalmic pharmaceutical company will receive an upfront payment, as well as additional milestone payments under the contract.BRIMOCHOLTM PF is being developed by Zhaoke Ophthalmology's in partnership with Tenpoint Therapeutics as a potential treatment for the correction of the loss of near vision associated with presbyopia.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}